3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
7
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
Anthracyclines
×
Clear all
NCT02622074
2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1
Completed
60 enrolled
26 charts